AnaptysBio
ANAB
121 hedge funds and large institutions have $1.85B invested in AnaptysBio in 2018 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 46 increasing their positions, 36 reducing their positions, and 29 closing their positions.
51% more call options, than puts
Call options by funds: $11.7M | Put options by funds: $7.74M
28% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 36
5% more capital inflows, than outflows
Capital inflows: $226M | Capital outflows: $215M
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.37% less ownership
Funds ownership: 108.67% → 108.3% (-0.37%)
6% less funds holding
Funds holding: 129 → 121 (-8)
28% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 29
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$74M |
| 2 |
Janus Henderson Group
London,
|
+$18.3M |
| 3 |
BlackRock
New York
|
+$14.1M |
| 4 |
Millennium Management
New York
|
+$12.4M |
| 5 |
Viking Global Investors
Stamford,
Connecticut
|
+$10.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PFM Health Sciences
San Francisco,
California
|
-$33.4M |
| 2 |
Eventide Asset Management
Boston,
Massachusetts
|
-$26.2M |
| 3 |
Redmile Group
San Francisco,
California
|
-$19.8M |
| 4 |
Marshall Wace North America
New York
|
-$13.8M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$13.2M |
ANAB Hedge Fund Activity: Q4 2018 in Review
121 of the 4,506 institutional investors tracked by Wall St. Rank reported a position in AnaptysBio (ANAB) for Q4 2018, worth a combined $1.85B — down 35% from $2.85B a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of ANAB and 21 opened new positions — a net loss of 8 holders — while 36 trimmed existing stakes and 46 added.
The largest buyer was Adage Capital Partners, adding an estimated $74M. The largest seller was PFM Health Sciences, cutting an estimated $33.4M.
- 121 institutional investors held AnaptysBio (ANAB) as of Q4 2018, down from 129 in Q3 2018.
- Funds reported $1.85B of AnaptysBio stock for Q4 2018, down 35% quarter-over-quarter.
- 21 funds opened new AnaptysBio positions in Q4 2018 and 29 closed out, a net change of -8 holders.
- The largest AnaptysBio buyer in Q4 2018 was Adage Capital Partners, an estimated $74M added.
- The largest AnaptysBio seller in Q4 2018 was PFM Health Sciences, an estimated $33.4M sold.
Based on aggregated 13F filings for Q4 2018.